MSD Enters into a Clinical Collaboration with IO to Evaluate IO102-IO103 + Keytruda as 1L Treatment of Metastatic Melanoma
Shots:
- The companies collaborated to evaluate IO’s IO102-IO103 + MSD’s Keytruda vs Keytruda alone in the P-III trial for patients with previously untreated unresectable or MM. Biomarker studies will also be conducted while IO will sponsor the trial & MSD will provide Keytruda
- The P-I/II trial of combination therapy in 30 patients with the same indication demonstrated ORR (73%) & CR rate (47%). The therapy can induce tumor regression & establish durable antitumor response while achieving a manageable tolerability profile
- IO102 & IO103 are the immune-modulatory vaccines targeting IDO & PD-L1. The therapy has received BTD from FDA for MM based on the P-I/II trial
| Ref: PR Newswire | Image: IO Biotech
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com